• People
  • Practices
  • Insights
    • Firm News
    • Press Releases
    • Publications
    • Webcasts
    • Podcasts
    • Subscribe
    • Media Contacts
  • Careers
    • Career Opportunities
    • Attorney Development
    • Contact Us
  • About
    • Our Story
    • Awards & Accolades
    • Offices
    • Diversity
    • Pro Bono
    • Alumni
    • Contact Us
  • Search
  • Biography
  • Education
  • Recent Publications
Profile Picture

Lauren J. Elliot

Lauren
Elliot

Partner

CONTACT INFO

lelliot@gibsondunn.com

TEL:+1 212.351.3848

FAX:+1 212.351.5358

New York

200 Park Avenue, New York, NY 10166-0193 USA

  • Print
  • |
  • Share
  • |
  • vCard

PRACTICE

Litigation Accounting Firm Advisory and Defense Class Actions Environmental Litigation and Mass Tort FDA and Health Care Labor and Employment Life Sciences

BIOGRAPHY

Lauren J. Elliot is a litigation partner in the New York office of Gibson, Dunn & Crutcher and a member of Gibson Dunn’s Life Sciences, Class Actions, Commercial Litigation and Labor & Employment Practice Groups.

Ms. Elliot has extensive experience litigating complex, multi-party and multi-jurisdictional, high-profile mass torts, commercial and employment cases in trial and appellate courts around the country for companies in the pharmaceutical, professional services and technology industries.  She has represented clients in matters involving antibiotics, consumer products, contraceptives, lead pigments, multi-vitamins, NSAIDs, pesticides, software systems, talc products, transgenic plants and vaccines.  Ms. Elliot defends labor and employment claims in class actions and individual lawsuits and in connection with state and federal government investigations.  She counsels clients on product liability risks and on a range of employment-related matters including leave and accommodation policies, COVID-19 liability risks and workplace vaccination policies.

Legal Media Group has named Ms. Elliot to its Expert Guides Guide to the World’s Leading Women in Business Law for Product Liability five times. She is a member of the Committee on Drugs and Medical Devices for the Defense Research Institute, and served two terms as a member of the Product Liability Committee for the Association of the Bar of the City of New York.

Ms. Elliot graduated from Brown University in 1989 with honors (International Relations) and received her Juris Doctor from the University of Chicago Law School in 1993.  Ms. Elliot is admitted to practice in New York.

Pharmaceutical and Biotech Litigation

  • Led product liability team in multi-year investigation for Board of Directors of pharmaceutical company, undertaken in response to shareholder demand after thousands of lawsuits were filed alleging that company’s product caused cancer. The investigation required analyzing scores of epidemiological and other scientific studies and six decades of internal documents, and conducting dozens of fact and expert witness interviews, culminating in a 350-page report that was publicly filed.
  • Served as national trial and appellate counsel to pharmaceutical company in its successful defense of close to 400 product liability cases alleging that childhood vaccines caused autism. Managed large litigation team (including local counsel in dozens of states), implemented our successful legal and scientific strategy, argued motions in courts around the country, and examined fact and expert witnesses. Outside the courtroom, presented legal and scientific arguments to State AGs who were considering (but ultimately did not pursue) cost recovery actions and was responsible for responding to the well-coordinated attacks by advocacy groups through the Internet and in the media.*
  • Represented pharmaceutical company in its defense of all New York cases arising out of alleged injuries from overuse of NSAIDs.*
  • Represented pharmaceutical company in its defense of all New York cases involving alleged injuries from use of a contraceptive implant.*
  • Represented pharmaceutical company in cases involving alleged injuries from use of tetracycline antibiotics.*
  • Represented European pharmaceutical company in dispute with its CMO over manufacturing facility’s FDA compliance which threatened ability to produce and supply the active pharmaceutical ingredient of pharmaceutical company’s orphan drug.
  • Represented pharmaceutical company in case alleging incorrect inventorship, copyright infringement, and common law torts, requiring two bench trials.*
  • Represented biotechnology company in multiple cases involving patents for making genes that code for insect resistance and inserting genes into crops.*
  • Advise clients on potential product liability risks associated with pharmaceutical products including in connection with planned corporate acquistions.
  • Advised pharmaceutical company in connection with dispute arising out of co-development and marketing agreement.

Employment Litigation/Counseling

  • Represents major technology company against individual and class claims alleging discrimination and retaliation.
  • Represents major technology company in responding to state and federal government agency investigations of leave and accommodations policies and practices.
  • Represented professional services firm in California and New York wage-and-hour class action lawsuits alleging violations of state labor laws and the Fair Labor Standards Act.
  • Advise clients on employment-related matters, including leave and accommodation policies and trainings, workplace vaccination policies, and COVID-19 liability risks.

Commercial Litigation

  • Represented professional services firm against highly publicized fraud and breach of contract claims seeking hundreds of millions of dollars brought by the City of Los Angeles in connection with client’s implementation of a customer billing information system. After our team uncovered criminal conduct, the City voluntarily dismissed its case with prejudice, the trial court awarded client $2.5 million in sanctions for discovery misconduct and City officials pleaded guilty to felonies.
  • Represented professional services firm in $1.8 billion fraud and negligent misrepresentation case brought by investors who allegedly relied on firm’s audit report to purchase debt in leveraged loan transaction.
  • Represented digital advertising company in putative class action alleging data privacy violations of the U.K General Data Protection Regulation.
  • Represented information technology services company in a software implementation action in the Eastern District of New York, involving allegations of breach of contract, fraudulent inducement to enter into a contract, negligent misrepresentation, breach of warranty and violations of New York General Business Law, Section 349.
  • Represented pharmaceutical company in action against insurance company for reimbursement of defense costs incurred in mass tort litigation.*
  • Represented high net worth individual against allegations of fraudulent conveyance and preference payment claims. Served as lead trial counsel in three-week Bankruptcy Court trial and secured dismissal of all claims.*

Publications, Speech Engagements & Programs

  • Presenter, “COVID-19 Vaccines: Employer Strategies and Consideration,” Gibson Dunn webcast (February 10, 2021)
  • Co-author, “An Employer Playbook for the COVID “Vaccine Wars”: Strategies and Considerations for Workplace Vaccination Policies,” PLA Article (February 4, 2021)
  • Co-author, “New York State Businesses Must Adhere to Strict Compliance Requirements as they Reopen,” GDC Client Alert (June 18, 2020)
  • Co-author, “Employer Liability and Defenses from Suit for COVID-19 Related Exposures in the Workplace,” GDC Client Alert (May 4, 2020)
  • Lead author, “Food Litigation: The New Frontier,” New York Law Journal (GC Edition, July 8, 2010)
  • Lead author, “No Small Matter: Indemnifying Prescribing Physicians and the Issues that Must be Considered,” DRI Drug and Medical Device Seminar (May 2005)
  • Guest Lecturer, Ethics: Discovery and Litigation, University of Chicago Law School (2008-2010)
  • Speaker, “No Small Matter: Indemnifying Prescribing Physicians and the Issues that Must be Considered,” DRI Drug and Medical Device Seminar (May 2005)

*Representations occurred prior to attorney’s association with Gibson Dunn.

EDUCATION

University of Chicago - 1993 Juris Doctor

Brown University - 1989 Bachelor of Arts

ADMISSIONS

New York Bar

RECENT PUBLICATIONS

Firm News - October 6, 2022 | Twenty-Two Gibson Dunn Lawyers Recognized in Expert Guides’ Women in Business Law
Client Alert - November 5, 2021 | OSHA Issues Vaccination and Testing Emergency Temporary Standard for Larger Employers
Webcasts - October 20, 2021 | Webcast: COVID-19 Vaccines: Employer Strategies and Considerations in the Era of Government Mandates
Firm News - October 7, 2021 | Seventeen Gibson Dunn Partners Recognized in Expert Guides’ Women in Business Law
Publications - March 9, 2021 | An Employer Playbook for the COVID “Vaccine Wars”: Strategies and Considerations for Workplace Vaccination Policies
Webcasts - February 10, 2021 | Webcast: COVID-19 Vaccines: Employer Strategies and Considerations
Client Alert - February 1, 2021 | An Employer Playbook For The Covid “Vaccine Wars”: Strategies And Considerations For Workplace Vaccination Policies (Updated) <a href="#_edn1" name="_ednref1">[1]</a>
Client Alert - December 14, 2020 | An Employer Playbook for the COVID “Vaccine Wars”
Firm News - September 22, 2020 | Thirteen Gibson Dunn Partners Recognized in Expert Guides’ Women in Business Law
Client Alert - June 18, 2020 | New York State Businesses Must Adhere to Strict Compliance Requirements As They Reopen
Client Alert - May 4, 2020 | Employer Liability and Defenses from Suit for COVID-19-Related Exposures in the Workplace
Client Alert - April 22, 2020 | Colorado and Georgia Plan to Relax COVID-19 Restrictions and Allow Some Businesses to Reopen
Client Alert - April 20, 2020 | California’s COVID-19 Executive Orders Create a Layered Patchwork of Rules That Are Sometimes Conflicting and Always Changing
Client Alert - April 18, 2020 | New York Governor v. New York City Mayor: Who Has the Last Word on New York City’s Business Shutdown?
Publications - April 16, 2020 | Trump Likely Doesn’t Have Power To Reopen Businesses
Client Alert - April 10, 2020 | New York Empire State Development Corporation Further Updates Guidance on Businesses Deemed Essential Under Governor Andrew Cuomo’s “New York State on PAUSE” Executive Order
Client Alert - April 2, 2020 | What Is an “Essential Business”? New York and California Take Different Approaches
Client Alert - April 1, 2020 | The Cybersecurity and Infrastructure Security Agency of the Department of Homeland Security Updates Essential Critical Infrastructure Workforce Guidance
Client Alert - March 27, 2020 | New York State Empire State Development Corporation Revises Guidance on Construction Businesses Deemed Essential Under New York Governor Andrew Cuomo’s “New York State on PAUSE” Executive Order
Client Alert - March 24, 2020 | Enforcement of New York Governor Andrew Cuomo’s March 20, 2020 Executive Order Restricting Non-Essential Business Activity
  • Sitemap
  • Client Extranet
  • Terms of Use and Legal Notices
  • Privacy Statement
  • Cookie Notice
  • Contact Us
© 2023 Gibson, Dunn & Crutcher LLP.  All rights reserved.  For contact and other information, please visit us at gibsondunn.com.
Top
Gibson Dunn uses cookies which are essential for our website to function. With your consent, we and third parties may also use non-essential cookies to collect information about your browsing activities, and improve the content, functionality and performance of our website. By clicking “Accept All”, you consent to the use of all cookies on our website as set out in our Cookie Notice. You can reject all non-essential cookies by clicking “Reject All”. Choose "Manage Cookies" to view and customize your cookie settings.
Manage CookiesACCEPT ALLREJECT ALL
Manage consent

Your Privacy Choices / Cookies

This website uses cookies – small text files stored on your device, when you visit a website - including third party cookies to collect information about your browsing activities and improve the content, functionality and performance of our website. Out of these cookies, the cookies that are categorized as Necessary Cookies are stored on your browser as they are essential for the operation of the website. You may accept all cookies, or reject all cookies other than Necessary Cookies.  If you visit us from a different device or browser, or clear cookies, then you may need to return to this screen to re-select your preferences.   Note that rejecting some of these cookies may have an effect on your browsing experience. Please note that if you do not make a selection below, only necessary cookies will be set.

You can learn more about our processing of your personal data by visiting our Privacy Policy.
Necessary
Always Enabled
Necessary cookies are essential for our website to function and cannot be switched off in our systems. They are usually set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in, or filling in forms. Without these cookies, our website will not operate properly.   Cookie Details
Analytics
These cookies are used to collect information on how you use our website, including information about the pages you visited, how long you visited and if you experienced any errors. We use this information to help us improve the quality of our website and monitor the level of activity on our website. They may be set by third parties whose services have been added to our pages. Cookie Details
Save & Accept